1-9 of 9
Gregory A. Otterson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Dwight H. Owen, Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou, Carly Pilcher, Sheryl-Ann Suffren, Gwen Christenson, Nancy Curtis, Megan Jukich, Emily Schwarz, Himanshu Savardekar, Ruthann Norman, Sarah Ferguson, Barbara Kleiber, Robert Wesolowski, William E. Carson, III, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah, Bhavana Konda
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 731–741.
https://doi.org/10.1158/1078-0432.CCR-22-1552
Published: 16 February 2023
View article titled, A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Open the PDF for A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms in another window
Includes: Supplementary data
Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1038–1047.
https://doi.org/10.1158/1078-0432.CCR-17-2289
Published: 28 February 2018
View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Open the PDF for The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) in another window
Includes: Supplementary data
Journal Articles

Mutant type specific lung cancer models for individualized treatment

Wenrui Duan, Li Gao, Xin Wu, Gregory A. Otterson, Miguel A. Villalona-Calero
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): B3.
Published: 15 August 2014
View article titled, Mutant type specific lung cancer models for individualized treatment
Journal Articles

Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

Gregory A. Otterson, Miguel A. Villalona-Calero, William Hicks, Xueliang Pan, John A. Ellerton, Scott N. Gettinger, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2466–2473.
https://doi.org/10.1158/1078-0432.CCR-09-3015
Published: 14 April 2010
View article titled, Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

Lionel D. Lewis, Antonius A. Miller, Gary L. Rosner, Jonathan E. Dowell, Manuel Valdivieso, Mary V. Relling, Merrill J. Egorin, Robert R. Bies, Donna R. Hollis, Ellis G. Levine, Gregory A. Otterson, Frederick Millard, Mark J. Ratain, for the Cancer and Leukemia Group B
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3302–3311.
https://doi.org/10.1158/1078-0432.CCR-06-2345
Published: 01 June 2007
View article titled, A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871
Open the PDF for A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871 in another window
Journal Articles

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1246–1252.
https://doi.org/10.1158/1078-0432.CCR-06-1096
Published: 22 February 2007
View article titled, Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs
Open the PDF for Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs in another window
Journal Articles

Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer

Tamila Kindwall-Keller, Gregory A. Otterson, Donn Young, Anterpreet Neki, Tamara Criswell, Gerard Nuovo, Richie Soong, Robert Diasio, Miguel A. Villalona-Calero
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (5): 1870–1876.
https://doi.org/10.1158/1078-0432.CCR-04-1727
Published: 08 March 2005
View article titled, Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer
Open the PDF for Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer

Miguel A. Villalona-Calero, Paul Ritch, Jose A. Figueroa, Gregory A. Otterson, Robert Belt, Edward Dow, Sebastian George, James Leonardo, Spence McCachren, G. Lance Miller, Manuel Modiano, Manuel Valdivieso, Richard Geary, Jennifer W. Oliver, Jon Holmlund
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6086–6093.
https://doi.org/10.1158/1078-0432.CCR-04-0779
Published: 24 September 2004
View article titled, A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-α, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer

Miguel A. Villalona-Calero, M. Guillaume Wientjes, Gregory A. Otterson, Steven Kanter, Donn Young, Anthony J. Murgo, Beth Fischer, Carrie DeHoff, Danny Chen, Teng-Kuang Yeh, SaeHeum Song, Michael Grever, Jessie L-S. Au
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3303–3311.
Published: 05 September 2003
View article titled, Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer in another window